LOGIN  |  REGISTER
C4 Therapeutics
Compass Therapeutics

Stevanato to Participate in Upcoming Investor Conferences

May 09, 2025 | Last Trade: US$24.42 0.76 3.21

PIOMBINO DESE, Italy / May 09, 2025 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in three upcoming investor conferences.

  • Wednesday, May 14, 2025, at 5:00 p.m. (PT) – Fireside chat at the 2025 Bank of America Securities Healthcare Conference in Las Vegas
  • Wednesday, June 4, 2025, at 1:20 p.m. (CT) – Presentation at the 45th Annual William Blair Growth Stock Conference in Chicago
  • Thursday, June 5, 2025, at 10:30 a.m. (ET) – Fireside chat at the Jefferies Global Healthcare Conference in New York City

A live webcast of each event will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section. Replays will remain available for approximately 90 days after each event.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical, and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value-added solutions to clients.

For more information, please visit: www.stevanatogroup.com.

Viking Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page